Additional file 3: of Deprescribing preventive cardiovascular medication in patients with predicted low cardiovascular disease risk in general practice – the ECSTATIC study: a cluster randomised non-inferiority trial
- Clare Luymes (4753356)
- Rosalinde Poortvliet (3717631)
- Nan van Geloven (185707)
- Margot de Waal (4753353)
- Yvonne Drewes (4753359)
- Jeanet Blom (601800)
- Nynke Smidt (791302)
- Willem Assendelft (3475136)
- Wilbert van den Hout (4753350)
- Wouter de Ruijter (293035)
- Mattijs Numans (3543974)
Publication date
January 2018
DOIAbstract
Cost-effectiveness analysis. Table S2. Costs (in £) for the preparation of the intervention, per selected patient. Table S3. Costs (in £) and QALYs per patient in usual care group and intervention group. Figure S1. EuroQol Utility at t = 0, t = 3, t = 6, t = 12 and t = 24 in the usual care group and the intention. Figure S2. Cost-effectiveness acceptability curve showing the probability that an attempt to deprescribe preventive cardiovascular medication is cost-effective compared to usual care. (DOCX 66 kb
Add to ORKG